Holen Sie sich die Stockscreener-App
20.35
4.41%
0.86
Handel nachbörslich:
20.58
0.23
+1.13%
Schlusskurs vom Vortag:
$19.49
Offen:
$19.57
24-Stunden-Volumen:
889.50K
Relative Volume:
0.64
Marktkapitalisierung:
$178.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-1.8073
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
+2.57%
1M Leistung:
-15.94%
6M Leistung:
+14.20%
1J Leistung:
+22.96%
1-Tages-Spanne:
$19.57
$20.58
1-Wochen-Bereich:
$18.53
$20.58
52-Wochen-Spanne:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Vergleichen Sie TNXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
20.35 | 170.85M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.17 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.58 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.31 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.83 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.02 | 33.75B | 398.11M | -1.03B | -868.57M | -5.7032 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Holding Corp. stock trend forecastTrade Entry Report & Reliable Price Breakout Signals - newser.com
Tonix’s fibromyalgia drug shows significant pain reduction in study - Investing.com
How to recover losses in Tonix Pharmaceuticals Holding Corp. stockTrade Exit Report & Low Drawdown Trading Strategies - newser.com
Sentiment analysis tools applied to Tonix Pharmaceuticals Holding Corp.July 2025 PostEarnings & Stepwise Swing Trade Plans - newser.com
Tonix’s fibromyalgia drug shows significant pain reduction in study By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Unveils Positive Trial Results for Tonmya - GuruFocus
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence - The Manila Times
Tonix PharmaceuticalsPrelim Q3 net revenue from product sales $3.3 millionSEC filing - MarketScreener
Tonix (Nasdaq: TNXP) reports Phase 3 Tonmya fibromyalgia data: Week 14 pain reduction - Stock Titan
Is Tonix Pharmaceuticals Holding Corp. stock a safe haven assetEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Is Tonix Pharmaceuticals Holding Corp. stock trading at a premium valuation2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
First patient dosed in MGH-Led FOCUS study of Tonix’s investigational intranasal Oxytocin product - Proactive financial news
Understanding Momentum Shifts in (TNXP) - news.stocktradersdaily.com
Tonix: Assessing Tonmya's Commercial Potential Ahead Of Q4 2025 Launch - Seeking Alpha
Tonix Pharmaceuticals (TNXP) Launches New Study for Rare Endocri - GuruFocus
Can Tonix Pharmaceuticals Holding Corp. recover in the next quarterPortfolio Risk Report & Real-Time Volume Spike Alerts - newser.com
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital - Yahoo Finance
Tonix Pharmaceuticals Holding Corp. stock daily chart insightsTrade Risk Report & Daily Price Action Insights - newser.com
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence - The Manila Times
Tonix Pharmaceuticals Announces Poster Presentation of Tonmya™ at 2025 American College of Rheumatology Convergence - Quiver Quantitative
Tonix Pharma (Nasdaq: TNXP) to present Tonmya fibromyalgia data at ACR 2025 on Oct 27 - Stock Titan
What analysts say about Tonix Pharmaceuticals Holding Corp stockSmall Cap Stock Opportunities & Small Investment Trading Growth - earlytimes.in
Analyzing Tonix Pharmaceuticals Holding Corp. with risk reward ratio chartsMarket Volume Summary & AI Driven Stock Movement Reports - newser.com
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
2.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):